Inhibikase Therapeutics (IKT) Change in Accrued Expenses (2020 - 2026)
Inhibikase Therapeutics' Change in Accured Expenses was $5.14 million in Q2 2026, compared with -$575,063 a year earlier.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Change in Accrued Expenses (2020 - 2026) Analysis & Trends
On a trailing twelve-month basis, Inhibikase Therapeutics' Change in Accured Expenses was $6.33 million through Jun 30, 2026, up 600.5% year-over-year; for FY2025, it was $1.4 million, up 233.6% from FY2024.
- In earlier years, Change in Accured Expenses was $420,075 in FY2024, -$138,481 in FY2023, -$317,324 in FY2022 and $2.08 million in FY2021.
- The Q2 2026 figure marks the highest quarterly Change in Accured Expenses in data going back to Q1 2020.
- Compared with a year earlier, Change in Accured Expenses was higher in four of the last six quarters, with growth averaging 164.0%.
- The best year-over-year quarter for Change in Accured Expenses over five years was Q4 2021 (growth of 755.7%); the worst was Q1 2026 (a decline of 94.8%).
- Per Business Quant data, IKT's Change in Accured Expenses in the three quarters before Q2 2026 was $43,372 (Q1 2026), $424,899 (Q4 2025) and $718,197 (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Accrued Exp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | - |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 2.41 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 983.00 Mn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | - |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | - |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | -87.00 Mn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 756.00 Mn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | - |
| 10 | Inhibikase Therapeutics | 281.11 Mn | -420.36 Mn | - | 2.74 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 2.74 Mn |
| Jun 30, 2026 | 5.14 Mn |
| Mar 31, 2026 | 43,372.00 |
| Dec 31, 2025 | 424,899.00 |
| Sep 30, 2025 | 718,197.00 |
| Jun 30, 2025 | -575,063.00 |
| Mar 31, 2025 | 833,219.00 |
| Dec 31, 2024 | 518,656.00 |
| Sep 30, 2024 | 126,849.00 |
| Jun 30, 2024 | -473,064.00 |
| Mar 31, 2024 | 247,634.00 |
| Dec 31, 2023 | 401,740.00 |
| Sep 30, 2023 | 27,288.00 |
| Jun 30, 2023 | 272,706.00 |
| Mar 31, 2023 | -840,215.00 |
| Dec 31, 2022 | 132,394.00 |
| Sep 30, 2022 | -1.34 Mn |
| Jun 30, 2022 | 32,176.00 |
| Mar 31, 2022 | 858,240.00 |
| Dec 31, 2021 | 810,751.00 |
API Access
Inhibikase Therapeutics Change in Accrued Expenses API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=change-in-accured-expenses&ticker=IKT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "change-in-accured-expenses", "ticker": "IKT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=change-in-accured-expenses&ticker=IKT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();